12/31/2024

DIVA Laboratories U.S., LLC

Gentlemen:

In connection with the audit of our financial statements for the year/period ending/ended 12/31/2024, please fill out the attached form to provide directly to our auditors Deloitte & Touche, 20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC, the following information on our holding of your stock:

1. Basic information;
2. Appropriation of earnings;
3. Securities pledged as collateral;
4. Directors;
5. Chair of the board and the chief executive officer; and
6. Outstanding stock.

If the space on the attached form is not enough for your answers, you may use additional sheets.

If you wish to discuss this confirmation request with our auditors, please contact Chao, Freda L. by fax (+886-2-4051-6888 Ext.:5660).

We will appreciate your prompt completion of this form. An addressed reply envelope is enclosed for your reply.

Very truly yours,

DIVA LABORATORIES, LTD.

_____ By:_____

Company Name Authorized Signature(s):

Return To: Chao, Freda L. Group No.: A10B-3 Confirmation No.: LTI-0002
Tel: +886 -2-2725-9988 Ext.: 5660 Fax: +886 -2-4051-6888 Ext.:5660

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Attached is the information on our Company's shares owned by DIVA LABORATORIES, LTD. as of and for the year/period ending/ended 12/31/2024.

DIVA Laboratories U.S., LLC

_____
Company

_____
Signature

_____
Title

_____
Date

Currency: _____

1. Basic information - As of 12/31/2024, the Investor owned the following securities of our company:

   Common stock, 1,150,000 shares, par value - $ 1
   Preferred stock, _____ shares, par value - $ _____
   ☑ Certificates issued: 1,150,000 shares
   ☐ Certificates unissued: _____ shares, composed of _____ shares subscribed in cash and _____ shares of stock dividends.

2. Appropriation of earnings during the year/period ended _____ (please attach the financial statements to this confirmation):

   ☐ Appropriation has not been determined.
   ☐ Earnings were not appropriated.
   ☐ Earnings were appropriated on: _____. The appropriations included:
   Cash dividends distributable to the Investor: $ _____
   Stock dividends distributable to the Investor: $ _____

3. Securities pledged as collateral:

   Name of the pledgee: _____
   Number of shares pledged: _____ shares with total par value of _____
   Date of pledge: _____

4. Directors

   ☐ The Investor is a director of our company.
   Name of the representative: _____
   ☐ The Investor is not a director of our company.

5. Name of the chair of the board: _____

   Name of the chief executive officer: _____

6. As of 12/31/2024, our outstanding stock and related account balances were as follows:

   Common stock, _____ shares
   Preferred stock, _____ shares
   Total shareholders' equity $ _____, net income $ _____
   ☐ The above information was audited by
   Name of accounting firm: _____,
   name of audit partner: _____.
   ☐ The above information was not audited.

7. Other remarks:

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC
Tel：+886 -2-2725-9988 Ext.: 5660 Mobile: +886-937856806
Fax: +886 -2-4051-6888 Ext.:5660 Group: A10B-3 Contact: 趙麟鳳

郵票黏貼處

DIVA Laboratories U.S., LLC

Case No.:

Company Name: DIVA LABORATORIES, LTD.

Confirmation No.: LTI-0002

DIVA Laboratories U.S., LLC

郵票黏貼處

20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Deloitte & Touche

Tel：+886-2-2725-9988 Ext.：5660 Mobile：+886-937856806
Fax：+886-2-4051-6888 Ext.:5660 Group：A10B-3 Contact：趙麟鳳

案件編號：

公司名稱：鈺緯科技開發股份有限公司

函證編號：LTI-0002